Wave Life Sciences WVE GB — Deferred Tax Assets Operating Loss Carryforwards
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsOperatingLossCarryforwards.
The official record: Wave Life Sciences’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Wave Life Sciences's gb — deferred tax assets operating loss carryforwards.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Wave Life Sciences's GB — deferred tax assets operating loss carryforwards?
- Wave Life Sciences (WVE) reported GB — deferred tax assets operating loss carryforwards of $414.7M in Q4 2025.
- How has Wave Life Sciences's GB — deferred tax assets operating loss carryforwards changed year-over-year?
- Wave Life Sciences's GB — deferred tax assets operating loss carryforwards increased by 22.2% year-over-year, from $339.5M to $414.7M.
- What does GB — deferred tax assets operating loss carryforwards mean?
- This metric represents the value of tax benefits derived from historical operating losses that can be carried forward to offset future taxable income. It is a significant asset for companies in growth or R&D-heavy phases, indicating potential future tax savings. Investors track this to estimate the company's ability to shield future profits from taxation.